We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
51
Evolent Health
EVH
$661M
$32.1M 0.51%
3,548,613
+523,591
+17% +$4.25M
PACB icon
52
Pacific Biosciences
PACB
$426M
$29.5M 0.47%
5,734,309
+3,360,522
+142% +$17.1M
TFX icon
53
Teleflex
TFX
$5.94B
$28.1M 0.45%
74,719
+15,605
+26% +$5.37M
HRC
54
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$26.9M 0.43%
237,286
+38,524
+19% +$4.06M
CDNA icon
55
CareDx
CDNA
$1.99B
$25.4M 0.4%
1,176,730
+454,075
+63% +$10.4M
QDEL icon
56
QuidelOrtho
QDEL
$1.15B
$25.3M 0.4%
337,528
+177,512
+111% +$11.5M
GKOS icon
57
Glaukos
GKOS
$9.22B
$21.9M 0.35%
402,148
– –
TMO icon
58
Thermo Fisher Scientific
TMO
$196B
$21.1M 0.33%
64,797
+7,561
+13% +$2.29M
HCM icon
59
HUTCHMED
HCM
$1.94B
$20.5M 0.33%
817,817
+29,619
+4% +$648K
GMED icon
60
Globus Medical
GMED
$10.4B
$19.9M 0.32%
337,837
+40,171
+13% +$2.18M
INSP icon
61
Inspire Medical Systems
INSP
$1.51B
$19.5M 0.31%
263,217
+19,760
+8% +$1.27M
WVE icon
62
Wave Life Sciences
WVE
$1.11B
$19.3M 0.31%
2,402,858
+850,000
+55% +$20.8M
GTHX
63
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$19.1M 0.3%
721,925
– –
MTEM
64
DELISTED
Molecular Templates, Inc.
MTEM
$18.1M 0.29%
+86,379
New +$12.4M
MOH icon
65
Molina Healthcare
MOH
$12B
$17.7M 0.28%
130,619
+45,380
+53% +$5.72M
PODD icon
66
Insulet
PODD
$11.6B
$17.4M 0.28%
101,430
+12,185
+14% +$2.03M
BIO icon
67
Bio-Rad Laboratories Class A
BIO
$8.18B
$17.3M 0.27%
46,785
+40,035
+593% +$14.1M
DXCM icon
68
DexCom
DXCM
$29.5B
$17.2M 0.27%
313,900
-361,648
-54% -$17.2M
WMGI
69
DELISTED
Wright Medical Group Inc
WMGI
$17.1M 0.27%
560,311
-243,980
-30% -$6.39M
OMCL icon
70
Omnicell
OMCL
$2.06B
$16M 0.25%
196,339
+24,693
+14% +$1.89M
CVS icon
71
CVS Health
CVS
$137B
$15.4M 0.24%
207,279
+101,591
+96% +$7.13M
HMSY
72
DELISTED
HMS Holdings Corp.
HMSY
$15.3M 0.24%
517,377
+105,405
+26% +$3.23M
IART icon
73
Integra LifeSciences
IART
$1.49B
$15M 0.24%
257,772
+44,215
+21% +$2.63M
ABMD
74
DELISTED
Abiomed Inc
ABMD
$15M 0.24%
87,839
-45,192
-34% -$8.38M
XENT
75
DELISTED
Intersect ENT, Inc
XENT
$14.2M 0.23%
570,902
+112,314
+24% +$2.28M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.